Oracle Alpha Inc. Makes New Investment in Arvinas, Inc. (NASDAQ:ARVN)

Oracle Alpha Inc. acquired a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,895 shares of the company’s stock, valued at approximately $490,000.

Other large investors have also modified their holdings of the company. RTW Investments LP purchased a new position in shares of Arvinas in the 4th quarter worth $173,427,000. Commodore Capital LP acquired a new stake in Arvinas during the fourth quarter worth about $41,160,000. Norges Bank purchased a new position in shares of Arvinas in the 4th quarter worth about $36,126,000. Boxer Capital LLC acquired a new position in shares of Arvinas in the 4th quarter valued at about $25,051,000. Finally, FMR LLC grew its holdings in shares of Arvinas by 10.6% during the 3rd quarter. FMR LLC now owns 4,868,295 shares of the company’s stock worth $95,613,000 after purchasing an additional 466,667 shares during the period. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on ARVN. Barclays lifted their price target on shares of Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Wells Fargo & Company reduced their target price on shares of Arvinas from $63.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, May 9th. Oppenheimer reiterated an “outperform” rating and issued a $80.00 price target (down from $95.00) on shares of Arvinas in a report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Friday, May 17th. Finally, Stifel Nicolaus lowered their target price on Arvinas from $72.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.13.

Arvinas Stock Performance

ARVN opened at $25.67 on Friday. The company has a market capitalization of $1.76 billion, a P/E ratio of -4.33 and a beta of 1.98. The company has a 50-day moving average of $32.42 and a 200-day moving average of $37.91. Arvinas, Inc. has a 1-year low of $13.57 and a 1-year high of $53.08.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.45. Arvinas had a negative return on equity of 64.79% and a negative net margin of 185.09%. The firm had revenue of $25.30 million during the quarter, compared to analyst estimates of $32.94 million. During the same period in the previous year, the company earned ($1.54) earnings per share. Arvinas’s quarterly revenue was down 22.2% on a year-over-year basis. As a group, sell-side analysts expect that Arvinas, Inc. will post -4.08 earnings per share for the current fiscal year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.